Younger atrial fibrillation (AFib) patients are most likely to benefit from more personalized, MRI-guided ablation treatments to correct irregular heart rhythms, according to a new artificial intelligence-guided analysis of results from the DECAAF II trial, one of the largest global studies of treatments for heart arrhythmias.
Mindbio Therapeutics CEO Issues Letter To Shareholders | Psychedelic Invest
VANCOUVER, BC / ACCESSWIRE / July 8, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the “Company” or “MindBio”), a leading biopharmaceutical company in psychiatric medicine development today issued